Clinical Trial Update: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial of pulsed inhaled nitric oxide in subjects with pulmonary fibrosis at risk for pulmonary hypertension was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Pulmonary Hypertension

Drugs mentioned

• pulsed inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Bellerophon Pulse Technologies | Conditions: Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Status: TERMINATED